[DNA repair pathways and non-small cell lung cancer: clinical perspectives]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA repair pathways maintain cellular integrity, but their dysfunction drives tumor development.
• Tumor cells often exhibit loss of function in DNA repair pathways, creating a potential vulnerability.
• Excessive genetic instability can trigger cancer cell death, suggesting therapeutic targeting opportunities.

Purpose of the Study:

• To explore the potential of targeting DNA repair pathways, specifically synthetic lethality, for innovative lung cancer treatments.
• To discuss the role of DNA repair proteins as prognostic and predictive biomarkers in lung cancer.
• To present principal DNA repair pathways and associated biomarkers in non-small cell lung cancer (NSCLC).

Main Methods:

• Review of DNA repair pathways including base excision repair (BER) and homologous recombination repair (HR).
• Discussion of synthetic lethality, exemplified by PARP1 inhibition in BRCA-mutated cancers.
• Analysis of biomarkers such as ERCC1, MSH2, PARP1, and BRCA1/2 in NSCLC.

Main Results:

• Inhibition of PARP1 induces cell death in cancer cells with BRCA1/2 mutations (synthetic lethality).
• DNA repair biomarkers (e.g., ERCC1) can predict response to chemotherapy (e.g., cisplatin) and radiotherapy.
• Pharmacologic modulation of DNA repair proteins may enhance the efficacy of anticancer therapies.

Conclusions:

• Synthetic lethality strategies targeting DNA repair pathways show promise for lung cancer treatment.
• DNA repair biomarkers are valuable for guiding therapeutic decisions and predicting patient outcomes in NSCLC.
• Modulating DNA repair mechanisms offers a promising avenue for improving lung cancer therapy.